Skip to main content

Cyteir Therapeutics, Inc. (CYT)

NASDAQ: CYT · IEX Real-Time Price · USD
17.43 -0.72 (-3.97%)
Oct 22, 2021 4:00 PM EDT - Market closed

Company Description

Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality.

Synthetic lethality represents a clinically validated approach to drug development and arises when there is a deficiency in either of two conditions that are tolerable alone in cells but lethal together.

Our lead program, CYT-0851, is in a phase 1/2 trial in adult patients with hematologic malignancies and solid tumors. If warranted by the phase 1/2 data, and subject to FDA agreement, we could initiate a potentially registrational trial in 2022 for the treatment of relapsed and/or refractory lymphoma and/or solid tumors.

We also plan to develop CYT-0851 in additional tumor settings as both a monotherapy and in combination with approved cancer therapeutics and plan to initiate dosing in a phase 1/2 trial that explores tolerability and preliminary activity of combinations with standard-of-care therapies in the second half of 2021.

Cyteir Therapeutics, Inc.
CountryUnited States
IPO DateJun 18, 2021
CEOMarkus Renschler, M.D.

Contact Details

128 Spring St, Building A, Suite 510
Lexington, MA 02421
United States
Phone857 285 4140

Stock Details

Ticker SymbolCYT
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
IPO Price$18.00
CIK Code1662244
ISIN NumberUS23284P1030
Employer ID45-5429901

Key Executives

Joseph S. ZakrzewskiIndependent Investor and Chairman
Dr. Markus F. Renschler M.D.President, Chief Executive Officer and Director
Timothy RombergerIndependent Director
Dr. Paul Secrist Ph.D.Chief Scientific Officer
Andrew W. GengosChief Business Officer
Dr. Kevin MillsCo-Founder
David G. GaieroVice President of Finance
Lisa A. HayesVice President of Investor Relations and Corporate Communications
Gale CohenVice President of Human Resources
Dr. Tom O'Shea Ph.D.Senior Vice President of Clinical Pharmacology and Preclinical Development